Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO Sells 10,896 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates sold 10,896 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the sale, the chief financial officer now directly owns 290,988 shares of the company’s stock, valued at approximately $1,009,728.36. This trade represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $3.43 on Friday. The firm has a fifty day moving average price of $3.55 and a 200 day moving average price of $4.05. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27. The stock has a market cap of $303.90 million, a PE ratio of -0.90 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. As a group, equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. raised its stake in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after acquiring an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Amylyx Pharmaceuticals in the fourth quarter valued at approximately $45,000. Alpine Global Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $45,000. RPO LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth $46,000. Finally, EntryPoint Capital LLC purchased a new position in Amylyx Pharmaceuticals in the 4th quarter valued at $53,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.